| Riffer E, Spiller J, Palmer R, et al.
Once daily clarithromycin extended-release vs twice-daily amoxicillin/clavulanate in patients with acute bacterial sinusitis: a randomized, investigator-blinded study. [Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial]
Curr Med Res Opin 2005 Jan; 21(1):61-70.
Abstract | Full Citation | Find Related Articles | | Berry V, Hoover J, Singley C, et al.
Comparative bacteriological efficacy of pharmacokinetically enhanced amoxicillin-clavulanate against Streptococcus pneumoniae with elevated amoxicillin MICs and Haemophilus influenzae. [Journal Article]
Antimicrob Agents Chemother 2005 Mar; 49(3):908-15.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Sethi S, Breton J, Wynne B
Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2,000/125 milligrams twice daily for 5 days versus amoxicillin-clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitis. [Clinical Trial, Journal Article, Randomized Controlled Trial]
Antimicrob Agents Chemother 2005 Jan; 49(1):153-60.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Sevillano D, Calvo A, Giménez MJ, et al.
Bactericidal activity of amoxicillin against non-susceptible Streptococcus pneumoniae in an in vitro pharmacodynamic model simulating the concentrations obtained with the 2000/125 mg sustained-release co-amoxiclav formulation. [Journal Article]
J Antimicrob Chemother 2004 Dec; 54(6):1148-51.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | File TM, Lode H, Kurz H, et al.
Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults. [Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial]
Antimicrob Agents Chemother 2004 Sep; 48(9):3323-31.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Sourgens H, Bertola MA, Verschoor JS, et al.
Amoxicillin/clavulanic acid (875/125): bioequivalence of a novel Solutab tablet and rationale for a twice-daily dosing regimen. [Clinical Trial, Journal Article, Randomized Controlled Trial]
Int J Clin Pharmacol Ther 2004 Mar; 42(3):165-73.
Abstract | Full Citation | Find Related Articles | | Garau J
Performance in practice: bacteriological efficacy in patients with drug-resistant S. pneumoniae. [Journal Article]
Clin Microbiol Infect 2004 Apr.:28-35.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Craig WA
Proof of concept: performance testing in models. [Journal Article, Review]
Clin Microbiol Infect 2004 Apr.:12-7.
Abstract | Full Citation | Find Related Articles | | Ojetti V, Migneco A, Zocco MA, et al.
Beta-lactamase inhibitor enhances Helicobacter pylori eradication rate. [Clinical Trial, Journal Article, Randomized Controlled Trial]
J Intern Med 2004 Jan; 255(1):125-9.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Rodrigues DC, Taba MJ, Novaes AB, et al.
Effect of non-surgical periodontal therapy on glycemic control in patients with type 2 diabetes mellitus. [Clinical Trial, Journal Article, Randomized Controlled Trial]
J Periodontol 2003 Sep; 74(9):1361-7.
Abstract | Full Citation | Find Related Articles |    |
|
| |
Advertise on this site.
|
